Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$25.17 USD
-1.18 (-4.48%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $25.16 -0.01 (-0.04%) 7:02 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Akero Therapeutics, Inc. [AKRO]
Reports for Purchase
Showing records 61 - 80 ( 108 total )
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Do Not Miss Part 1 on Monday of Our 4-Part NASH COVID-19 Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Yas'' Weekly Recap of Our Key Notes and 20 Doc Calls Upcoming in 2Q20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The New Kid on the Block Could Be a Major Player in NASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
17 Doc Calls Across 9 Therapeutic Areas Upcoming in 2Q20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Yas'' Weekly Recap of Our Key Notes and 16 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap: Imminent Key Catalyst in 12-Week MRI-PDFF Data in NASH Patients; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q19 - Ahead of 1Q20 Readout, Back to Undervalued
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BALANCED Potency in NASH; Key Data Catalysts in 1Q20 and 2Q20; Initiate Buy, $33 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Do Not Forget to Dial-in to Our NASH Call Today with Dr. Arun Sanyal at 1PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Our NASH Expert Call with Dr. Arun Sanyal Moved to Friday, Feb. 21, at 1PM ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Do Not Forget to Dial-in to Our Call Today with Dr. Arun Sanyal at 12pm
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Yas'' Weekly Recap of Our Key Notes and 10 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Join our Part 2 NASH Call on Feb. 18 with Dr. Arun Sanyal
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Can''t Miss Takeaways from our NASH Fibrosis Expert Call with Dr. Scott Friedman
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
With 1Q20 Topline Data, Let''s Plot Our Data Scenarios - Must Read
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Do Not Miss Our NASH Fibrosis Call with Dr. Scott Friedman at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y